IL149580A0 - Analgesic compositions containing buprenorphine - Google Patents

Analgesic compositions containing buprenorphine

Info

Publication number
IL149580A0
IL149580A0 IL14958000A IL14958000A IL149580A0 IL 149580 A0 IL149580 A0 IL 149580A0 IL 14958000 A IL14958000 A IL 14958000A IL 14958000 A IL14958000 A IL 14958000A IL 149580 A0 IL149580 A0 IL 149580A0
Authority
IL
Israel
Prior art keywords
compositions containing
containing buprenorphine
analgesic compositions
analgesic
buprenorphine
Prior art date
Application number
IL14958000A
Other languages
English (en)
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of IL149580A0 publication Critical patent/IL149580A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL14958000A 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine IL149580A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14
PCT/GB2000/004372 WO2001035942A2 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine

Publications (1)

Publication Number Publication Date
IL149580A0 true IL149580A0 (en) 2002-11-10

Family

ID=26316086

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14958000A IL149580A0 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine
IL149580A IL149580A (en) 1999-11-19 2002-05-09 Analgesic preparations containing buprenorphine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149580A IL149580A (en) 1999-11-19 2002-05-09 Analgesic preparations containing buprenorphine

Country Status (31)

Country Link
US (4) US6995169B2 (ko)
EP (1) EP1242087B1 (ko)
JP (1) JP4745576B2 (ko)
KR (1) KR100726699B1 (ko)
CN (1) CN100431543C (ko)
AR (1) AR031682A1 (ko)
AT (1) ATE262335T1 (ko)
AU (1) AU777259B2 (ko)
BR (1) BR0015580A (ko)
CA (1) CA2392013C (ko)
CO (1) CO5261517A1 (ko)
CZ (1) CZ303160B6 (ko)
DE (1) DE60009346T2 (ko)
DK (1) DK1242087T3 (ko)
ES (1) ES2214334T3 (ko)
GB (1) GB2356348B (ko)
HK (1) HK1055389A1 (ko)
HU (1) HU229565B1 (ko)
IL (2) IL149580A0 (ko)
MX (1) MXPA02004978A (ko)
NO (1) NO321965B1 (ko)
NZ (1) NZ519023A (ko)
PL (1) PL199727B1 (ko)
PT (1) PT1242087E (ko)
RO (1) RO121174B1 (ko)
RU (1) RU2255737C2 (ko)
SI (1) SI21025B (ko)
SK (1) SK286888B6 (ko)
TR (1) TR200400653T4 (ko)
TW (1) TW550070B (ko)
WO (1) WO2001035942A2 (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
WO2005123039A1 (en) 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
WO2008051889A1 (en) 2006-10-24 2008-05-02 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
ES2572157T3 (es) * 2007-09-03 2016-05-30 Nanotherapeutics Inc Composiciones en forma de partículas para la administración de fármacos poco solubles
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
RS56344B1 (sr) 2010-12-22 2017-12-29 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
KR20140075807A (ko) 2010-12-23 2014-06-19 퍼듀 퍼머 엘피 탬퍼 저항성 고체 경구 투여 형태
AU2012311293B2 (en) 2011-09-19 2014-02-20 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
IL300868A (en) 2012-06-06 2023-04-01 Orexigen Therapeutics Inc Methods for treating overweight and obesity
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9216175B2 (en) * 2013-09-10 2015-12-22 Insys Pharma, Inc. Sublingual buprenorphine spray
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
EP4100012A4 (en) * 2020-02-05 2024-02-07 Summit Biosciences Inc MEDICINAL PRODUCTS INTENDED TO BE ADMINISTERED BY INTRANASAL ROUTE AND ASSOCIATED USES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
JP2004501094A (ja) * 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド オピオイドアゴニストの効力を増強するか、またはオピオイドアゴニストの有害な副作用を減弱するための新規な組成物および方法

Also Published As

Publication number Publication date
NO20022330D0 (no) 2002-05-15
HUP0203588A3 (en) 2005-01-28
GB2356348A (en) 2001-05-23
SK8762002A3 (en) 2002-12-03
DE60009346D1 (de) 2004-04-29
US20060069113A1 (en) 2006-03-30
AU1529701A (en) 2001-05-30
CA2392013C (en) 2009-08-11
HK1055389A1 (en) 2004-01-09
WO2001035942A2 (en) 2001-05-25
MXPA02004978A (es) 2003-01-28
AU777259B2 (en) 2004-10-07
GB0028088D0 (en) 2001-01-03
CA2392013A1 (en) 2001-05-25
EP1242087B1 (en) 2004-03-24
SI21025B (sl) 2008-04-30
KR20020058022A (ko) 2002-07-12
DE60009346T2 (de) 2005-02-10
HUP0203588A2 (hu) 2003-03-28
NO321965B1 (no) 2006-07-31
US7402591B2 (en) 2008-07-22
JP2003514013A (ja) 2003-04-15
CO5261517A1 (es) 2003-03-31
RU2255737C2 (ru) 2005-07-10
GB2356348B (en) 2002-02-06
RO121174B1 (ro) 2007-01-30
SK286888B6 (sk) 2009-07-06
WO2001035942A3 (en) 2002-06-13
US20060058332A1 (en) 2006-03-16
AR031682A1 (es) 2003-10-01
US20060058333A1 (en) 2006-03-16
RU2002116361A (ru) 2004-01-27
TR200400653T4 (tr) 2004-04-21
ES2214334T3 (es) 2004-09-16
CN100431543C (zh) 2008-11-12
BR0015580A (pt) 2002-07-09
PL355330A1 (en) 2004-04-19
ATE262335T1 (de) 2004-04-15
PT1242087E (pt) 2004-06-30
WO2001035942A9 (en) 2002-11-28
TW550070B (en) 2003-09-01
US6995169B2 (en) 2006-02-07
HU229565B1 (hu) 2014-02-28
CZ303160B6 (cs) 2012-05-09
KR100726699B1 (ko) 2007-06-13
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
NZ519023A (en) 2004-11-26
IL149580A (en) 2007-05-15
JP4745576B2 (ja) 2011-08-10
CN1413110A (zh) 2003-04-23
PL199727B1 (pl) 2008-10-31
NO20022330L (no) 2002-07-04
EP1242087A2 (en) 2002-09-25
DK1242087T3 (da) 2004-07-19

Similar Documents

Publication Publication Date Title
IL149580A0 (en) Analgesic compositions containing buprenorphine
GB9902520D0 (en) Composition
AP2001002273A0 (en) Rescorcinol composition
GB9919683D0 (en) Composition
GB9925709D0 (en) Composition
GB2366984B (en) Composition
GB9914446D0 (en) Composition
GB2357714B (en) Composition
HU9700801D0 (en) New analgesic compositions
GB9914582D0 (en) Composition
GB9912409D0 (en) Compounds and compositions
GB9906607D0 (en) Oral composition
GB9906689D0 (en) Composition
GB9915435D0 (en) Composition
GB9919955D0 (en) Composition
GB9914714D0 (en) Composition
GB9907270D0 (en) Composition
GB9907146D0 (en) Composition
GB9906690D0 (en) Composition
GB9919953D0 (en) Composition
GB9914715D0 (en) Composition
GB9918591D0 (en) Composition
GB9900394D0 (en) Composition
GB9911933D0 (en) Composition
GB9914712D0 (en) Composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed